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ABSTRACT
The identification of novel helper T (Th) cell subsets, i.e., IL-17-producing Th cells (Th17 cells) and regulatory T
cells (Treg cells), provided new insight into our understanding of the molecular mechanisms involved in the de-
velopment of infectious and autoimmune diseases as well as immune responses, and thus led to revision of the
classic Th1Th2 paradigm. Several current lines of evidence from gene-deficient mice indicate that IL-17 and
Th17 cells, but not IFN-γ and Th1 cells, are responsible for the development of autoimmune diseases such as
murine arthritis and encephalomyelitis, which have classically been considered to be Th1-mediated disorders.
Th17 cells may also contribute to the pathogenesis of classically recognized Th2-mediated allergic disorders.
In this review, we summarize the current knowledge regarding IL-17 and Th17 cells and discuss their potential
roles in the pathogenesis of allergic disorders.
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INTRODUCTION
Allergic disorders, which affect approximately 30% of
the population in developed countries, are genetically
determined andor environmentally affected multifac-
torial, refractory diseases. These disorders are associ-
ated with chronic inflammation characterized by in-
flux of a large number of eosinophils and accumula-
tion of mast cells in the lesions and increased IgE
production.1,2 Leukemic patients who did not have
any allergic symptoms developed allergic diseases
such as asthma or rhinitis after therapeutic transplan-
tation of bone marrow stem cells from donors who
had such allergic disorders,3,4 suggesting that bone
marrow-derived immune cells contribute to the devel-
opment of allergic disorders. In particular, several
lines of evidence generated in gene- and immune cell-
deficient mice clearly demonstrated that helper T
(Th) cells play central roles in the accumulationacti-
vation of eosinophils and mast cells and in IgE pro-
duction by B cells, contributing to the pathogenesis
of allergic disorders.1,2
Since the discovery of two distinct types of Th cells
(IFN-γ-producing Th1 cells and IL-4-producing Th2
cells) in mice by Coffman and colleagues in 1986,5
mutual regulation between Th1 cells and Th2 cells
(Th1Th2 balance) has been considered to be impor-
tant for homeostatic maintenance of the immune sys-
tem in the whole body. For example, dysregulation of
the Th1Th2 balance leads to excessive Th1 cell or
Th2 cell activation, resulting in the development of
autoimmune diseases associated with accumulation
of Th1 cells or induction of allergic diseases due to
accumulation of Th2 cells, respectively.6 Thus, the
concept of a Th1Th2 balance provided the basis for
understanding the molecular mechanisms of immune
responses andor disease development and has been
widely accepted as a “paradigm” of the immune sys-
tem for the past two decades.7
On the other hand, changes in autoimmune dis-
eases that could not be explained by the Th1Th2
paradigm were also observed in several settings: un-
expectedly, IFN-γIFN-γR-deficiency or-neutralization
resulted in exacerbation, rather than attenuation, of
development of autoimmune diseases such as murine
encephalomyelitis,8-10 arthritis,11,12 uveitis13,14 and ne-
phritis,15 which have classically been considered to
be Th1-mediated diseases. Studies for non-Th1Th2-
cell-based mechanisms for the pathogenesis of auto-
immune diseases identified two additional Th cell
subsets, i.e., IL-17-producing Th cells (Th17 cells)
and regulatory T cells (Treg cells). These cells pro-
vided new insight into the molecular mechanisms in-
volved in immune responses andor disease develop-
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ment, and led to revision of the classic Th1Th2 para-
digm in such settings. Likewise, these new T cell sub-
sets, particularly Th17 cells, may also contribute to
the pathogenesis of classically recognized Th2-
mediated allergic disorders. In this review, we sum-
marize current knowledge regarding IL-17 and Th17
cells and discuss their potential roles in the patho-
genesis of allergic disorders.
TH17 CELLS (THIL-17 CELLSTHi CELLS)
In 2000, Infante-Duarte et al. first demonstrated that
IL-17-producing T cells were a distinct Th population
from Th1 cells and Th2 cells in both mice and hu-
mans.16 Subsequently, the importance of IL-17-
producing T cells rather than Th1 cells for the devel-
opment of certain diseases, e.g., attenuated develop-
ment of contact hypersensitivity17 and arthritis,18 was
demonstrated in IL-17-deficient mice. These observa-
tions clearly indicated the involvement of IL-17 in the
pathogenesis of such disorders, but the molecular
mechanisms involving IL-17 andor IL-17-producing
T cells remained unclear. Based on the findings of
Infante-Duarte et al., Aggarwal et al. reported that IL-
23 can promote in vitro IL-17 production by certain
Th cells which are categorized as neither Th1 cells
nor Th2 cells.19 Then, Murphy et al. found that IL-23-
deficient mice had fewer IL-17-producing T cells dur-
ing autoimmune diseases such as collagen-induced
arthritis and were able to completely suppress the
disease development.20 Almost simultaneously,
Nakae et al. reported that IL-17-deficient mice exhib-
ited marked suppression of the development of
collagen-induced arthritis.21 These observations indi-
cate that IL-23-mediated IL-17 production, rather than
IL-12-mediated IFN-γ induction, is crucial for the de-
velopment of autoimmune diseases. In 2005, Langrish
et al. provided direct in vivo evidence that IL-17-
producing Th cells (called “ThIL-17 cells”) induced by
IL-23, rather than IFN-γ-producing Th1 cells induced
by IL-12, played a central role in the induction of
murine encephalomyelitis.22 In support of this notion,
Harrington et al. and Park et al. established the basis
of the molecular mechanism in the development of
IL-17-producing T cells (called “Th17 cells” or “in-
flammatory T cells; Thi cells”) that require distinct
cytokines (IL-23 but not IL-12 and IL-4) and transcrip-
tion factors from those of Th1 cells and Th2 cells.23,24
In 2006, IL-6 in the presence of TGF-β rather than IL-
23 was identified as the crucial combination for differ-
entiation of IL-17-producing Th cells in vitro25 and in
vivo26,27 in mice. Moreover, Ivanov et al. identified
ROR-γt as a key transcription factor for Th17 cell dif-
ferentiation.28 In addition, in the absence of IL-6, IL-
21 also induces IL-17-producing Th cell differentia-
tion.29-31 However, IL-6 plus TGF-β-mediated IL-17-
producing T cells lack pathogenic activities since
such IL-17-producing T cells also secrete an anti-
inflammatory cytokine, IL-10.32 In mice, IL-23 is re-
quired for the differentiation from IL-6 plus TGF-β-
mediated IL-17+, IL-10+ nonpathogenic T cells to
pathogenic Th17 cells which do not produce IL-10.32
On the other hand, IL-27 suppresses Th17 cell-
differentiation33,34 by inducing IL-10- and IFN-γ-
producing T-bet+ Tr1 cells from IL-6 plus TGF-β-
mediated IL-17+, IL-10+ T cells in mice.32,35-37 Like IL-
27, the newly identified IL-12-related cytokine IL-35,
which is produced by Foxp+ Treg cells, suppresses
Th17 cell-mediated immune responses in mice, al-
though the precise molecular mechanism remains
unknown.38,39 In contrast, human Th17 cell differen-
tiation requires a cytokine milieu that is distinct from
that needed for mouse Th17 cell differentiation: TGF-
β is not essential for human Th17 cell differentiation.
In humans, combination of IL-1β and IL-23, or IL-1β
and IL-6, but not IL-1β, IL-6 or IL-23 alone, signifi-
cantly induces Th17 cells as well as IL-17+ and IFN-γ+
Th cells.40,41 The schemes of Th differentiation in hu-
mans and mice are summarized in Figure 1.
IL-17 AND ALLERGIC ASTHMA
Allergic asthma is considered to be a Th2-dominant
chronic inflammatory disease of the lungs.42,43 In-
creased Th2-cytokine and IgE levels and accumula-
tionactivation of Th2 cells, eosinophils and mast
cells are observed in asthmatic lungs.42,43
IL-17 mRNA andor proteins were reported to be
increased in the lungs, sputum, bronchoalveolar lav-
age (BAL) fluids or sera from asthmatics,44-50 and the
levels of IL-17 correlated with the degree of severity
of airway hypersensitivity in asthmatic patients,47 im-
plying a contribution of IL-17 to the pathogenesis of
asthma. Supporting those observations, IL-17 can po-
tentiate bronchial fibroblast, epithelial cell and
smooth muscle cell activation. That is, IL-17 enhances
IL-6, IL-8, IL-11 and CXCL1Groα production by hu-
man bronchial fibroblasts,45 β-defensin-2, ICAM-1, IL-
8, CXCL1, CCL20, G-CSF, MUC5B and MUC5AC ex-
pressionproduction by human bronchial epithelial
cells,51-57 and IL-6 and IL-8 production by human air-
way smooth muscle cells (Fig. 2).58,59 Nevertheless,
these IL-17-mediated inflammatory mediators do not
seem to contribute to the development of Th2-
mediated eosinophil-dominant allergic asthma, since
IL-8 and CXCL1Groα are potent chemoattractant
factors for neutrophils, and IL-6 and G-CSF are impor-
tant for granulopoiesis, especially neutrophil develop-
ment. In addition, IL-17 inhalation led to induction of
neutrophilia rather than eosinophilia in the airways of
rodents.60,61 However, these observations may pro-
vide us with new insight into the pathogenesis of
“non-Th2-type” asthma.
As “non-Th2-type” asthma, several investigators
found asthmatic patients who had neutrophil-, rather
than eosinophil-, rich pulmonary inflammation.62-68
The heterogeneity in the symptoms of asthma has
been classified as atopic and non-atopic67 and eosino-
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Fig. 1 The revised scheme of Th cel diferentiation in humans and mice. In the mouse, naïve T cels diferenti-
ate into Th1 cels in the presence of IL-12 or IL-27, Th2 cels in the presence of IL-4, TSLP or IL-25, Th17 cels 
in the presence of IL-23 after TGF-β1 plus IL-6- or IL-21-mediated cel diferentiation, Tr1 cels in the presence of 
IL-27 after TGF-β1 plus IL-6- or IL-21-mediated cel diferentiation, and Th3/iTreg cels in the presence of TGF-β1 
and IL-2. In man, naïve T cels diferentiate into Th1 cels in the presence of IL-2, Th2 cels in the presence of IL-
4 and Th17 cels in the presence of IL-1β plus IL-6 or IL-1β plus IL-23. The mechanisms of human Tr1 and 
Th3/iTreg cel diferentiation remain unclear.
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philic and non-eosinophilic.64,68
Amin et al. demonstrated that atopic asthmatics
showed Th2-type airway inflammation characterized
by increased IL-4+ and IL-5+ cells and eosinophils in
bronchial biopsies and increased serum IgE levels,
whereas non-atopic asthmatics exhibited non-Th2
type airway inflammation characterized by increased
IL-8+ cells and neutrophils in bronchial biopsies, and
no elevation of serum IgE.67 On the other hand, in-
creased mast cell accumulation was observed in both
atopic and non-atopic patients irrespective of the IgE
level.67 Clear structural differences were also ob-
served between atopic and non-atopic patients: the
degree of epithelial damage and the thickness of the
tenascin and laminin layer were greater in atopic
asthmatics than in non-atopic asthmatics (Fig. 3).67
Wenzel et al. examined the heterogeneity of infil-
trated cells in lung biopsy from mild, moderate and
severe asthmatic patients and healthy subjects.64
Mild and moderate asthmatics showed predomi-
nantly eosinophilic inflammation, while severe asth-
matics showed neutrophilic inflammation.64 More-
over, these neutrophil-associated severe asthmatics
also can be divided into two populations, eosinophil-
negative and -positive.64 The counts of other cell
types (CD3+ cells, CD4+ cells, CD8+ cells, CD68+ cells
and mast cells) in the biopsy were comparable in
healthy subjects and mild, moderate and non-
eosinophil but neutrophil-associated severe asthmat-
ics.64 However, these cells, including neutrophils and
eosinophils, as well as pathological changes in the
lungs were dramatically increased in eosinophil- and
neutrophil-associated severe asthmatics compared
with other populations.64 Gibson et al. also presented
further evidence of the heterogeneity of cell types
and inflammatory mediator levels in the sputum from
eosinophilic and non-eosinophilic asthmatics, having
found increased neutrophils and elevated IL-8 in non-
eosinophilic asthmatics (Fig. 3).68 Importantly, the se-
verity of asthma correlated well with the number of
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Fig. 2 IL-17 activities in various types of cels. IL-17 promotes (indicated as↑) and suppresses (indicated as
↓) the expression and/or production of various molecules in epithelial, endothelial and smooth muscle cels, fibro-
blasts, keratinocytes, macrophages and dendritic cels.
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neutrophils.62-66,68 Otherwise, the dichotomous classi-
fications by steroid sensitivity may be similar to the
classification by eosinophilic and non-eosinophilic
asthma. Eosinophilic mildmoderate asthmatics are
sensitive to steroid treatment, while non-
eosinophilicneutrophilic or eosinophilicneutro-
philic severe asthmatics are resistant (Fig. 3).69
Douwes et al. reported that various studies from
1995 to 2000 using specimens from asthmatics who
were defined as having eosinophil-dominant features
actually contained data from non-eosinophil
neutrophil-dominant asthmatics.70 Likewise, although
IL-17 levels were significantly increased in the spu-
tum of severe asthmatics,49,50 the heterogeneity of
asthmatics who showed increased IL-17 levels was
not clearly characterized in some reports.44-48 Thus,
IL-17 may contribute to the pathogenesis of non-
atopic andor non-eosinophilneutrophil-dominant
asthma, and it may be a new marker for classification
of such non-Th2 type asthma.
IL-17 IN A TH2 CYTOKINE-MEDIATED AND
EOSINOPHIL-DOMINANT MOUSE ASTHMA
MODEL
The well-established model of Th2-type asthma in
mice is an allergic response against ovalbumin
(OVA), fungal antigens and cockroach antigens. Sen-
sitization with such antigens and subsequent intrana-
sal or aerosol challenge with the same antigens in
mice results in the development of airway inflamma-
tion and elevated airway hypersensitivity responses
(AHR). However, the responses vary as a result of dif-
ferent sensitization protocols, immunization routes,
antigens and mouse backgrounds.71,72 For instance,
in the case of OVA-induced AHR, the requirement for
immune cells and mediators is affected by use of ad-
juvants during the sensitization. Although mast cells
and B cell-derived IgE-mediated mast cell activation
are considered to be responsible for the development
of asthma, mast cells,73,74 B cells75 and IgE-FcεRI-,76
IL-1-IL-1R-,77,78 TNF-TNFR-79 and CCR880,81-mediated
responses are not essential for induction of eosino-
philic airway inflammation and AHR in mice sensi-
tized with OVA emulsified in alum as an adjuvant. In
contrast, such cells and mediators are essential for
the induction of AHR andor eosinophilic airway in-
flammation in mice sensitized by repeated injection of
OVA without any adjuvant.74,76-79,82 Moreover, even if
the sensitization protocols are the same, the pheno-
types differ among the genetic background.71,72,83 For
example, distinct responses are observed in TNF-
and TNFR-deficient mice,79,84-87 IL-1R1-deficient
Th17 and Allergy
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Fig. 3 Classification of “atopic and non-atopic” and “eosinophilic and non-eosinophilic” asthma. 
Atopic patients show elevated serum IgE levels and increased Th2 cels and eosinophils, while non-
atopic patients show increased IL-8＋ cels and neutrophils without elevation of serum IgE. In addi-
tion, atopic patients can be roughly divided into two populations, eosinophilic and non-eosinophilic 
asthmatics. Eosinophilic asthmatics who are steroid-responsive and mild to moderate in severity 
show Th2 cytokine- and eosinophil-dominant inflammation, whereas non-eosinophilic asthmatics 
who are steroid-resistant and have refractory symptoms show non-Th2 cytokine- and neutrophil-
dominant inflammation.
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mice78,88 and CCR8-deficient mice80,81,89 between the
129 (Ola or SvJ) ×B6 mixed, C57BL6 and BALBc
backgrounds. However, irrespective of different sen-
sitization protocols and mouse genetic backgrounds,
similar features of pathogenesis characterized by
Th2-dominant and eosinophil-rich pulmonary inflam-
mation are observed: eosinophils make up approxi-
mately 80―90% of the total cells in BAL fluids, while
neutrophils generally comprise less than 5―10%.
Using the intraperitoneal OVA with alum sensitiza-
tion protocol, IL-17-deficient mice of a 129Sv x B6
mixed background exhibited normal AHR as as-
sessed by enhanced respiratory pause (Penh) re-
sponses,17 although Penh evaluation is currently con-
sidered to be inappropriate for measurement of air-
way function.90,91 A normal total BAL cell count, but
increased IL-4 and IL-5 levels, in the BAL fluid were
observed in IL-17-deficient mice of 129Sv x B6
mixed background (Fig. 4A).17
Using a repeated intraperitoneal OVA sensitization
protocol (without adjuvant), Hellings et al. demon-
strated that BALBc mice treated with anti-IL-17 neu-
tralizing mAb (clone 50104 from R&D Systems; 50
μgmouse intraperitoneally) before and during the
phase of repeated OVA challenge exhibited compara-
ble Penh responses and BAL eosinophil counts, but
increased IL-5 levels in the BAL fluid, relative to mice
treated with control Ab (Fig. 4B).92 Notably, the BAL
neutrophil count and also the blood and bone marrow
neutrophils were reduced in anti-IL-17 mAb-treated
BALBc mice.92
Using a repeated epicutaneous OVA sensitization
protocol (employing a gauze patch containing OVA
solution, without adjuvant), He et al. reported that
BALBc mice treated with anti-IL-17 neutralizing
mAb (clone 50104 from R&D systems; 100 μgmouse
intravenously) during the last epicutaneous sensitiza-
tion showed reduced Penh responses, but a normal
BAL eosinophil count in comparison with mice
treated with control Ab (Fig. 4B).93 Similar to the
findings of Hellings et al., the BAL neutrophil count
was reduced by anti-IL-17 mAb treatment.93 He et al.
also demonstrated that the epicutaneous OVA sensiti-
zation potently induced Th17 cells in draining LNs
and OVA-challenged lungs and neutrophil recruit-
ment in BALs after OVA challenge (―20% neutrophils
and ―50% eosinophils in the total BAL cells), while the
intraperitoneal OVA with alum sensitization induced
Oboki K et al.
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Fig. 4 Efects of IL-17 inhibition on Th2 cytokine-mediated and eosinophil-dominant murine asthma. A) Phenotypes in IL-
17-deficient or IL-17R-deficient mice. B) Phenotypes in mice treated with anti-IL-17 neutralizing mAb.
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weak Th17 responses and neutrophil recruitment
(less than 5% neutrophils and ―70% eosinophils in the
total BAL cells).93
Thus, these observations indicate no or little contri-
bution of IL-17 to the induction of Th2-mediated
eosinophil recruitment and AHR in murine asthma.
On the contrary, using the subcutaneous OVA with
alum sensitization protocol, Schnyder-Candrian et al.
demonstrated that IL-17R (IL-17RA)-deficient mice of
a C57BL6 background revealed profoundly impaired
eosinophil recruitment and a reduced IL-5 level in the
BAL fluid (Fig. 4A).94 The authors concluded that the
reduced responses were caused by impaired antigen-
specific Th cell induction during the sensitization
phase in IL-17R-deficient mice.94 IL-17-deficient mice
(129SvxB6 mixed background) also showed im-
paired antigen-specific Th cell induction during in-
traperitoneal sensitization with OVA emulsified in
alum, but normal AHR and airway inflammation.17
The distinct phenotypes between IL-17-deficient mice
and IL-17R-deficient mice may be caused by the dif-
ferences in their genetic backgrounds (129SvxB6
mixed background vs. C57BL6 background) and im-
munization routes (intraperitoneally vs. subcutane-
ously). He et al. showed that the intraperitoneal OVA
with alum immunization could induce Th17 cells in
the spleen, although the levels were less than those
by repeated epicutaneous OVA immunization without
any adjuvant.93 On the other hand, Schnyder-
Candrian et al. showed that subcutaneous OVA with
alum immunization could not induce IL-23-
responding Th17 cells in the spleen, although it did
induce Th17 cells in the draining LNs.94 Thus, the de-
gree of induction of splenic Th17 cells after OVA sen-
sitization is influenced by the immunization route
(epicutaneouslly >> intraperitoneally > subcutane-
ously) and may affect the different contributions of
pathology to Th2-mediated and eosinophil-dominant
murine asthma.
IL-17F, which, like IL-17 is a member of the IL-17
cytokine family of molecules, binds to IL-17R (con-
sisting of IL-17RA and IL-17RC) and has similar
pathological activities to IL-17. IL-17F overexpression
in lungs induces airway neutrophilia.95 Therefore, it
can be speculated that the distinct phenotypes be-
tween IL-17-deficient mice (characterized by Nakae et
al.17) and IL-17R-deficient mice (characterized by
Schnyder-Candrian et al.94) may be explained by a
compensatory effect of IL-17F on IL-17-deficiency.
Schnyder-Candrian et al. also investigated the role
of IL-17 in the challenge phase of OVA-induced
murine asthma. The OVA challenge in the presence
of anti-IL-17 mAb (clone 50104 from R&D Systems; 5
μgmouse, intranasally) in the challenge phase re-
sulted in exacerbated eosinophil recruitment in BAL
fluids (Fig. 4B).94 In contrast, OVA challenge in the
presence of rIL-17 led to attenuated responses.94 This
inhibitory activity of IL-17 is attributed to down-
regulation of chemokine CCL17 (TARC) production
by bone marrow-derived cultured DCs and lung
cells.94 These observations suggest that IL-17 plays a
protective role in the induction of Th2-mediated and
eosinophil-dominant inflammation in the challenge
phase of murine asthma. However, except for the dif-
ferent routes of OVA sensitization as described
above, the apparent differences in the effects of anti-
IL-17mAb treatment reported by Hellings et al.92 and
He et al.93 versus by Schnyder-Candrian et al.94 may
have reflected, at least in part, the different timing
and routes of Ab injection, i.e., systemic Ab admini-
stration (intravenously and intraperitoneally) by Hell-
ings et al.92 and He et al.,93 and local Ab administra-
tion (intranasally) by Schnyder-Candrian et al. (Fig. 4
B).94
Taken together, IL-17 may play a role in Th2
cytokine-mediated and eosinophil-dominant mouse
asthma by promoting allergen-specific Th cell induc-
tion in the sensitization phase and by inhibiting the
local allergic response in the challenge phase, de-
pendent at least in part on the experimental protocol
used.
IL-17 IN A TH17 CELL-MEDIATED AND
NEUTROPHIL-DOMINANT MOUSE ASTHMA
MODEL USING DO11.10 AND OTII MICE
As described above, IL-17 may contribute to the
pathogenesis of neutrophil-rich non-atopic or severe
asthma rather than that of eosinophil-rich atopic or
mildmoderate asthma. However, for investigating
the potential role of IL-17 in neutrophil-associated
asthma, the Th2-mediated and eosinophil-dominant
murine asthma model may not be appropriate.
BALBc-DO11.10 transgenic mice, which overex-
press OVA-specific TCR genes in CD4+ T cells, exhib-
ited airway inflammation after OVA inhalation with-
out prior sensitization with OVA.17,96,97 Like non-
atopic asthmatics, the inflammation in OVA-inhaled
DO11.10 mice is characterized by a predominant in-
flux of neutrophils rather than eosinophils in the air-
ways, without an increase in serum IgE.96,97 Similarly,
OVA-specific TCR-expressing C57BL6-OTII trans-
genic mice98 also exhibited neutrophil-dominant air-
way inflammation after OVA inhalation without prior
OVA sensitization.99 Moreover, Th1 cells and Th17
cells, but not Th2 cells, are increased in BAL cells
from OVA-inhaled DO11.10 or OTII mice.99 In asso-
ciation with this notion, IFN-γ and IL-17, but not IL-4,
IL-5 or IL-13, are increased in the BAL fluids of these
mice.96,99 After OVA inhalation, prior treatment with
anti-IFN-γ neutralizing Ab did not exert any influence
upon neutrophil recruitment, but significantly aug-
mented eosinophil recruitment, in the BAL fluids of
DO11.10 mice.96 IFN-γ-deficient OTII mice exhibited
increased neutrophils as well as eosinophils in BAL
fluids after OVA inhalation.99 In contrast, airway neu-
trophilia and AHR were profoundly impaired in IL-17-
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deficient DO11.10 mice17 and IL-17-deficient OTII
mice.99 These observations indicate that IL-17Th17
cells rather than IFN-γTh1 cells are responsible for
airway neutrophilia in the non-atopic asthma-like
model using DO11.10 and OTII mice (DO11.10OTII
model). In particular, the IL-17-induced airway neu-
trophil influx was highly dependent on TNF.99
In accordance with there being no elevation of
OVA-specific IgG1 and IgE in the DO11.10OTII
model, IgAg-FcR signals were not necessary for the
airway neutrophilia.99 However, notably, IgAg-FcR-
independent mast cell activation was crucial for the
event: Th17 cell-derived IL-17 promoted IgAg-FcR-
independent mast cell-TNF production, resulting in
enhanced airway neutrophilia in the OTII model that
resembled non-atopic asthma.99
The importance of the Th17IL-17-mast cellTNF
axis is also shown by the neutrophil recruitment in
Th2 cytokine-mediated, IgEMast cell-dependent and
eosinophil-dominant murine asthma induced by re-
peated OVA sensitization without any adjuvant.79,100
Both IL-17 and TNF can induce IL-8 and IL-6 pro-
duction by human bronchial epithelial cells, but the
extent of that induction is much less than that by
TNF.101 However, IL-17 can amplify TNF-mediated
IL-8 and IL-6 production.101 Additive or synergistic ef-
fects of IL-17 on TNF-mediated immune responses
have also been observed with several cell types.102,103
Like IL-17, TNF can induce airway neutrophilia and
AHR in healthy subjects.104 TNF levels in sputum
from non-eosinophilic (neutrophilic) asthmatic pa-
tients are higher than those in eosinophilic pa-
tients.105 TNF-positive mast cells were increased in
the airway submucosa in biopsies from asthma pa-
tients.106,107 Anti-TNF therapy reduced the severity of
the disease in severe asthmatics (including small re-
ductions in both eosinophils and neutrophils in the
sputum),107-109 but not the pulmonary eosinophilia in
patients with mild or moderate asthma.110 Thus, the
Th17IL-17-mast cellTNF axis may be involved in
the development of not only non-atopic asthma but
also severe asthma.
IL-17 IN A TH17 CELL-MEDIATED AND
NEUTROPHIL-DOMINANT MOUSE ASTHMA
MODEL CREATED BY T CELL TRANSFER
After OVA inhalation, airway inflammation can be in-
duced by passive transfer of T cells from DO11.10
mice into naïve mice that had not been sensitized
with OVA. Indeed, Cohn et al. demonstrated that
naïve BALBc mice engrafted in vitro with DO11.10
Th2 cells induced by IL-4 (DO11.10 Th2 cells →
BALB mice), or with DO11.10 Th1 cells induced by
IL-12 (DO11.10 Th1 cells → BALB mice), exhibited
eosinophil-dominant or neutrophil-dominant airway
inflammation.111 Based on the observations in the in-
tact DO11.10OTII mouse model noted above, how-
ever, the Th1-mediated neutrophilia may be influ-
enced by other cell contaminations such as Th17
cells. In support of this, it was reported that BALBc
mice engrafted with DO11.10 Th17 cells, which were
generated with TGF-β, IL-6, IL-1β, TNF and IL-23 in
vitro (DO11.10 Th17 cells → BALB mice), showed
airway neutrophilia after OVA inhalation.112 Interest-
ingly, the authors also demonstrated the involvement
of IL-17 and IL-17F in airway neutrophilia. Both re-
combinant IL-17 and IL-17F inhalation induced airway
neutrophilia in mice, but the effects of IL-17 were
much more potent than those of IL-17F. Further-
more, the airway neutrophilia in OVA-inhaled DO
11.10 Th17 cells → BALB mice was suppressed by
treatment with anti-IL-17 mAb but not anti-IL-17F
mAb, indicating that Th17 cell-derived IL-17 rather
than IL-17F plays the central role in such settings.112
T-bet, which is a transcription factor, plays a cen-
tral role in Th1 cell development (Fig. 1).113 T cellB
cell-deficient Rag-2-deficient mice engrafted with T-
bet-deficient DO11.10 CD4+ T cells, which include
many Th17 cells and Th2 cells but few Th1 cells in
comparison with wild-type DO11.10 CD4+ T cells, ex-
hibited increased neutrophils as well as eosinophils
in the BAL fluid after OVA challenge.114 The increase
in neutrophils, but not the increase in eosinophils, in
the BAL fluid from Rag-2-deficient mice engrafted
with T-bet-deficient DO11.10 CD4+ T cells was attenu-
ated by treatment with anti-IL-17 mAb (clone 50104
from R&D Systems; 150 μgmouse, intraperitoneally)
(Fig. 4B).114 Thus, these observations indicate that
Th17 cells (IL-17 but not IL-17F), rather than Th1
cells and Th2 cells, are responsible for neutrophil re-
cruitment in the passive Th cell transfer murine
asthma model.
IL-17 IN CHEMICALLY INDUCED MOUSE
ASTHMA MODEL
Airway inflammation induced by chemicals such as
toluene diisocyanate (TDI),115,116 hezamethylene di-
isocyanate (HDI)117,118 and dinitrofluorobenzene
(DNFB)119,120 is used as a murine model resembling
occupational asthma or sick buildinghouse syn-
drome and characterized by an influx of neutrophils.
Although TNF and mast cells are responsible for the
DNFB-induced neutrophilic airway inflamma-
tion,119,120 the possible contribution of IL-17 to the
diseases remains unknown. However, it was shown
that IL-17 is important for the neutrophil recruitment
in TDI-induced airway inflammation.121 These limited
observations suggest that IL-17 may be involved in
the pathogenesis of occupational asthma or sick
buildinghouse syndrome.
IL-17 IN ALLERGIC RHINITIS, CONJUNCTI-
VITIS AND FOOD ALLERGY
Allergic rhinitis, conjunctivitis and food protein-
induced allergic enterocolitis are considered to be
typical Th2 cytokine-dominant diseases. It was re-
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ported that IL-17 was detectable in the nasal fluids
from patients with allergic and viral rhinitis, although
the IL-17 levels were much higher in viral rhinitis
than in allergic rhinitis.122 Both eosinophils and neu-
trophils had infiltrated the inflammatory lesions of pa-
tients with conjunctivitis, and increased IL-8 levels
and mast cell activation were also observed.123,124 In
certain cases, patients with food-protein enterocolitis
syndrome exhibited a significant increase in neutro-
phils.125 In humans and rodents, the roles of IL-17
and Th17 cells in such allergic diseases remain to be
elucidated. However, the limited observations to date
imply that IL-17 may contribute to neutrophil recruit-
ment by inducing IL-8 or mast cell activation.
IL-17 IN ALLERGIC DERMATITIS
It was recently shown that IL-17 and Th17 cells con-
tribute to the pathogenesis of psoriasis, which is an
autoimmune skin disorder.126 IL-17 can promote IL-6,
IL-8, Groα, GM-CSF, SCF and ICAM-1 expression
production127-129 by keratinocytes and CCL20 (MIP-
3α) expression by dermal fibroblasts, dermal mi-
crovascular endothelial and dendritic cells, and
keratinocytes.130 Although IL-17 was increased more
in skin biopsy specimens from patients with acute-
phase atopic dermatitis compared with the chronic
phase,131 the precise roles of IL-17 and Th17 in the
disease development remain to be elucidated.
Classically, contact dermatitis (contact hypersensi-
tivity; CHS) was regarded as one form of delayed-
type hypersensitivity (DTH) reaction. However,
based on the findings in gene-deficient mice, it is
known that CHS develops due to different molecular
mechanisms from DTH.132 MHC class I-deficient
mice, which lack CD8+ T cells, showed attenuated
CHS responses, while MHC class II-deficient mice,
which lack CD4+ T cells, showed exacerbated dis-
ease.133 These observations indicate that CD8+ T cells
are an effector, while CD4+ T cells are a regulator, in
such settings. On the other hand, studies using CD4-
deficient and CD8-deficient mice indicated that both
CD4+ T cells and CD8+ T cells are required as effec-
tor cells for CHS responses.134 Supporting this, it was
further reported that MHC class II-deficiency also led
to attenuation of CHS.135
As in the development of autoimmune diseases,
CHS responses are also considered to induce exces-
sive IFN-γ-producing Th1 cells and Tc1 cells.132,134
However, CHS responses induced by oxazolone,136
TNCB136,137 and DNFB138,139 developed normally in
IFN-γ- and IFN-γR1-deficient mice. IFN-γR2-deficient
mice (129xB6 mixed background) showed reduced
CHS responses induced by FITC,140 while IFN-γ-
deficient mice (C57BL6 background) exhibited nor-
mal CHS responses induced by FITC and oxazolone
(Nakae S; unpublished observation). Thus, these ob-
servations indicate that IFN-γ is not essential for the
development of CHS, and at least, CHS does not
seem to be a Th1Tc1-mediated response.
Oxazolone-induced CHS developed normally in IL-4-
deficient mice having a 129xB6,141 BALBc142 or C57
BL6143 background, while TNCB- or DNFB-induced
CHS was decreased in IL-4-deficient mice having a
BALBc or C57BL6 background,142-144 but not in IL-
13-deficient mice having a 129xB6 mixed back-
ground.145 Mice deficient in STAT-6, which is essen-
tial for IL-4 and IL-13 signal transduction, exhibited
attenuated CHS responses induced by oxazolone,
TNCB, DNFB or FITC.135,146 Thus, these observa-
tions indicate that Th2-cytokines, rather than Th1-
cytokines, are important for the chemical induction of
CHS responses, although the responses are affected
by the mouse background and chemicals used.
Nickel-specific Th clones which were established
from patients with allergic contact dermatitis ex-
pressed IL-17,128,129 implying a contribution of IL-17
and Th17 cells to the disease. IL-17-deficient mice of
129xB6 mixed background exhibited reduced CHS
induced by DNFB and TNCB.17 FITC- and oxazolone-
induced CHS responses were also attenuated in IL-
17-deficient mice having a C57BL6 background
(Nakae S; unpublished observations). The attenuated
CHS responses were caused by a defect in hapten-
specific Th cell induction.17 Moreover, it was shown
that IL-17-producing CD8+ T cells (Tc17 cells), but
not Tc1 cells, are a central player in the induction of
CHS responses.147
Taken all together, both Th2-cytokines and Th17-
cytokines, but not Th1-cytokines, are responsible for
the development of CHS in mice.
CONCLUSIONS
In addition to its role in the development of autoim-
mune diseases, IL-17 may play roles in the develop-
ment of various allergic diseases that have classically
been considered to be Th1- or Th2-mediated disor-
ders. Moreover, IL-17 may be a new marker of dis-
ease progression and a new target for therapy.
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